Search Results
Further analysis of QuANTUM-First: the impact of allo-HCT combined with quizartinib in FLT3-ITD+ AML
Quizartinib for frontline FLT3-ITD+ AML: updated results from the QuANTUM-First trial
QuANTUM-First: the benefit of quizartinib based on pre-transplant MRD status
Update on QuANTUM-First: quizartinib + SOC chemotherapy & as continuation therapy in FLT3-ITD+ AML
The QuANTUM-First study
Quizartinib for FLT3-Mutated AML
Role of FLT3 Inhibitors and Other Novel Agents in AML
Quizartinib in the Treatment Landscape of AML
FDA approval of quizartinib - Vanflyta
Potential approval of quizartinib in AML & its place in the AML treatment regimen
The prognostic value of FLT3-ITD residual disease in AML
Quizartinib provides clinical benefit in R/R FLT3-ITD AML
